[{"orgOrder":0,"company":"Royalty Pharma","sponsor":"PTC Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved","graph3":"Royalty Pharma","amount2":0.65000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0.65000000000000002,"dosageForm":"Oral","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Funding","leadProduct":"Zavegepant","moa":"CGRP receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Royalty Pharma","amount2":0.45000000000000001,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0.45000000000000001,"dosageForm":"Spray","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"9","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Ivacaftor","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Royalty Pharma","amount2":0.65000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0.65000000000000002,"dosageForm":"","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"BioCryst Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2020","type":"Funding","leadProduct":"Berotralstat","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Royalty Pharma","amount2":0.33000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0.33000000000000002,"dosageForm":"","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Minerva Neurosciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Seltorexant","moa":"Selective orexin-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Royalty Pharma","amount2":0.16,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.16,"dosageForm":"Tablet","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Divestment","leadProduct":"Cabozantinib","moa":"TYK","graph1":"Oncology","graph2":"Approved","graph3":"Royalty Pharma","amount2":0.39000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.39000000000000001,"dosageForm":"Tablet","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Dicerna Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2021","type":"Acquisition","leadProduct":"Lumasiran","moa":"HO-1","graph1":"Genetic Disease","graph2":"Approved","graph3":"Royalty Pharma","amount2":0.23999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0.23999999999999999,"dosageForm":"Subcutaneous Injection","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"MorphoSys","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Large molecule","year":"2021","type":"Partnership","leadProduct":"Guselkumab","moa":"IL-23","graph1":"Immunology","graph2":"Approved","graph3":"Royalty Pharma","amount2":2.0299999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":2.0299999999999998,"dosageForm":"","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Cytokinetics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Financing","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac Myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Royalty Pharma","amount2":0.45000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.45000000000000001,"dosageForm":"Tablet","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Blueprint Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Pralsetinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Royalty Pharma","amount2":0.34000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.34000000000000002,"dosageForm":"Capsule","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Arrowhead Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Olpasiran","moa":"Lipoprotein","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Royalty Pharma","amount2":0.40999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.40999999999999998,"dosageForm":"Injectable\/Injection","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"Nusinersen Sodium","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Royalty Pharma","amount2":1.1299999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":1.1299999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Theravance Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Divestment","leadProduct":"Fluticasone Furoate","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Royalty Pharma","amount2":1.55,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":1.55,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Zavegepant HCl","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Royalty Pharma","amount2":0.47999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.47999999999999998,"dosageForm":"Spray","sponsorNew":"Royalty Pharma \/ Pfizer Inc","highestDevelopmentStatusID":"12","companyTruncated":"Royalty Pharma \/ Pfizer Inc"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Karuna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Xanomeline","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Royalty Pharma","amount2":0.5,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.5,"dosageForm":"Capsule","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Ferring Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"Nadofaragene Firadenovec-vncg","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Royalty Pharma","amount2":0.5,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.5,"dosageForm":"Injectable\/Injection","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Ascendis Pharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2023","type":"Financing","leadProduct":"lonapegsomatropin-tcgd","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Royalty Pharma","amount2":0.14999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0.14999999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"PTC Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Risdiplam","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Royalty Pharma","amount2":1.5,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":1.5,"dosageForm":"Solution","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Olanzapine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Royalty Pharma","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.13,"dosageForm":"Injection","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Arrowhead Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Olpasiran","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Royalty Pharma","amount2":0.40999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.40999999999999998,"dosageForm":"Injection","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"ImmuNext Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2024","type":"Acquisition","leadProduct":"Frexalimab","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Royalty Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Agios Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Vorasidenib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Royalty Pharma","amount2":0.91000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.91000000000000003,"dosageForm":"Tablet, Film Coated","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Cytokinetics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Aficamten","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Royalty Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Agios Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Vorasidenib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Royalty Pharma","amount2":0.91000000000000003,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"14","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Ascendis Pharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2024","type":"Financing","leadProduct":"Palopegteriparatide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Royalty Pharma","amount2":0.14999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"14","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Syndax Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Agreement","leadProduct":"Axatilimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Royalty Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"14","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Geron","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Financing","leadProduct":"Imetelstat","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Royalty Pharma","amount2":0.25,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"14","companyTruncated":"Royalty Pharma \/ Royalty Pharma"}]
Find Clinical Drug Pipeline Developments & Deals by Royalty Pharma
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
